JP2008530132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530132A5 JP2008530132A5 JP2007555338A JP2007555338A JP2008530132A5 JP 2008530132 A5 JP2008530132 A5 JP 2008530132A5 JP 2007555338 A JP2007555338 A JP 2007555338A JP 2007555338 A JP2007555338 A JP 2007555338A JP 2008530132 A5 JP2008530132 A5 JP 2008530132A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amino acid
- acid residues
- seq
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 24
- 125000000539 amino acid group Chemical group 0.000 claims 20
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 claims 14
- 101710131691 Interleukin-31 receptor subunit alpha Proteins 0.000 claims 14
- 108020003175 receptors Proteins 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010059284 Epidermal necrosis Diseases 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 241000700584 Simplexvirus Species 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65328305P | 2005-02-14 | 2005-02-14 | |
| US69486705P | 2005-06-29 | 2005-06-29 | |
| US71676105P | 2005-09-13 | 2005-09-13 | |
| PCT/US2006/005148 WO2006088855A1 (en) | 2005-02-14 | 2006-02-14 | Methods of treating skin disorders using an il-31ra antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008530132A JP2008530132A (ja) | 2008-08-07 |
| JP2008530132A5 true JP2008530132A5 (cg-RX-API-DMAC10.html) | 2009-04-02 |
Family
ID=36572470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555338A Pending JP2008530132A (ja) | 2005-02-14 | 2006-02-14 | Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (9) | US20060182743A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1858924A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2008530132A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2006214404B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2594490A1 (cg-RX-API-DMAC10.html) |
| IL (2) | IL184371A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2007009718A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2006088855A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1188830T3 (da) * | 1999-06-02 | 2010-04-26 | Chugai Pharmaceutical Co Ltd | Nyt hæmopoietinreceptorprotein NR10 |
| EP1221482B1 (en) | 1999-09-27 | 2005-12-28 | Chugai Seiyaku Kabushiki Kaisha | Hemopoietin receptor protein, nr12 |
| US20030096339A1 (en) | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
| WO2004003140A2 (en) * | 2002-01-18 | 2004-01-08 | Zymogenetics, Inc. | Cytokine receptor zcytor17 multimers |
| US9738700B2 (en) | 2002-01-18 | 2017-08-22 | Zymogenetics Inc. | ZCYTOR17 heterodimeric cytokine receptor |
| RU2490276C2 (ru) | 2002-01-18 | 2013-08-20 | Займоджинетикс, Инк. | Новый лиганд рецептора цитокина zcytor17 |
| EP1858924A1 (en) * | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| JP4927762B2 (ja) | 2005-02-14 | 2012-05-09 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| US8101183B2 (en) * | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| CN101198624B (zh) * | 2005-05-06 | 2012-10-10 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| EP2001906A2 (en) | 2006-01-10 | 2008-12-17 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| ES2544888T3 (es) * | 2006-06-08 | 2015-09-04 | Chugai Seiyaku Kabushiki Kaisha | Prevención o remedio para enfermedades inflamatorias |
| EP2061811A2 (en) | 2006-09-01 | 2009-05-27 | ZymoGenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| AU2008204823A1 (en) | 2007-01-10 | 2008-07-17 | Zymogenetics, Inc | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| CA2708065C (en) * | 2007-12-05 | 2015-02-24 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for pruritus |
| TWI548418B (zh) * | 2007-12-05 | 2016-09-11 | 中外製藥股份有限公司 | Anti-NR10 / IL-31RA antibody and its use |
| SI2796466T1 (en) | 2007-12-07 | 2018-01-31 | Zymogenetics, Inc. | Molecules of Humanized Specifics Specifiable for IL-31 |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| JP5139517B2 (ja) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | 抗ｎｒ１０抗体、およびその利用 |
| KR20160062207A (ko) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| TWI544077B (zh) | 2009-03-19 | 2016-08-01 | 中外製藥股份有限公司 | Antibody constant region change body |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2014176696A1 (en) * | 2013-04-30 | 2014-11-06 | Université de Montréal | Novel biomarkers for acute myeloid leukemia |
| HUE056580T2 (hu) | 2013-05-30 | 2022-02-28 | Kiniksa Pharmaceuticals Ltd | Onkosztatin-M-receptor antigénjét kötõ fehérjék |
| TW201537175A (zh) * | 2013-06-28 | 2015-10-01 | Chugai Pharmaceutical Co Ltd | 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法 |
| FI3284480T3 (fi) | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
| US10946078B2 (en) * | 2016-04-27 | 2021-03-16 | Benchmark Animal Health Ltd. | Treatment of canine atopic dermatitis |
| JP7127859B2 (ja) | 2016-11-09 | 2022-08-30 | ノース カロライナ ステート ユニバーシティ | キメラタンパク質を用いたアレルギー疾患の治療 |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| PL3749353T3 (pl) * | 2018-02-09 | 2025-12-08 | Galderma Holding SA | Nemolizumab w leczeniu atopowego zapalenia skóry z przeczosami o nasileniu od umiarkowanego do ciężkiego |
| CA3093709C (en) | 2018-03-16 | 2024-03-26 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| JP7449234B2 (ja) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | 獣医学使用のためのインターロイキン３１モノクローナル抗体 |
| WO2019183437A1 (en) | 2018-03-23 | 2019-09-26 | North Carolina State University | Methods and compositions for antibody to high affinity receptor for ige |
| KR20210079278A (ko) * | 2018-09-06 | 2021-06-29 | 시다라 세라퓨틱스, 인코포레이티드 | 바이러스 감염의 치료를 위한 조성물 및 방법 |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗ｉｌ３１抗体 |
| WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
| WO2021123092A1 (en) | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Bispecific caninized antibodies for treating atopic dermatitis |
| CA3189847A1 (en) | 2020-09-01 | 2022-03-10 | Naoki Fukazawa | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
| TW202607038A (zh) | 2020-10-19 | 2026-02-16 | 美商碩騰服務公司 | 犬及貓抑瘤素Ｍ受體β之抗體及其用途 |
| WO2025167991A1 (zh) * | 2024-02-07 | 2025-08-14 | 武汉人福创新药物研发中心有限公司 | 一种靶向il-31ra的抗体或其抗原结合片段及其应用 |
| WO2026032397A1 (en) * | 2024-08-09 | 2026-02-12 | Zai Lab (Shanghai) Co., Ltd. | Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK1188830T3 (da) | 1999-06-02 | 2010-04-26 | Chugai Pharmaceutical Co Ltd | Nyt hæmopoietinreceptorprotein NR10 |
| EP2075253A1 (en) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Compositions and methds for the diagnosis and treatment of disorders involving angiogensis |
| US20030096339A1 (en) * | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
| EP1325115B1 (en) * | 2000-06-26 | 2016-07-27 | ZymoGenetics, Inc. | Cytokine receptor zcytor17 |
| US20030059871A1 (en) | 2000-10-06 | 2003-03-27 | Cosman David J. | Hematopoietin receptors HPR1 and HPR2 |
| WO2002077230A1 (fr) | 2001-03-26 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Variants d'epissage nr10 |
| RU2490276C2 (ru) | 2002-01-18 | 2013-08-20 | Займоджинетикс, Инк. | Новый лиганд рецептора цитокина zcytor17 |
| WO2004003140A2 (en) * | 2002-01-18 | 2004-01-08 | Zymogenetics, Inc. | Cytokine receptor zcytor17 multimers |
| US7303896B2 (en) | 2002-02-25 | 2007-12-04 | Genentech, Inc. | Nucleic acid encoding novel type-1 cytokine receptor GLM-R |
| JP4927762B2 (ja) | 2005-02-14 | 2012-05-09 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| EP1858924A1 (en) | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| CN101198624B (zh) | 2005-05-06 | 2012-10-10 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| EP2001906A2 (en) | 2006-01-10 | 2008-12-17 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| EP2061811A2 (en) | 2006-09-01 | 2009-05-27 | ZymoGenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
-
2006
- 2006-02-14 EP EP06720729A patent/EP1858924A1/en not_active Withdrawn
- 2006-02-14 MX MX2007009718A patent/MX2007009718A/es active IP Right Grant
- 2006-02-14 AU AU2006214404A patent/AU2006214404B2/en not_active Ceased
- 2006-02-14 CA CA002594490A patent/CA2594490A1/en not_active Abandoned
- 2006-02-14 JP JP2007555338A patent/JP2008530132A/ja active Pending
- 2006-02-14 US US11/353,451 patent/US20060182743A1/en not_active Abandoned
- 2006-02-14 WO PCT/US2006/005148 patent/WO2006088855A1/en not_active Ceased
-
2007
- 2007-07-03 IL IL184371A patent/IL184371A/en not_active IP Right Cessation
-
2009
- 2009-03-13 US US12/404,162 patent/US7871618B2/en not_active Expired - Lifetime
-
2010
- 2010-08-19 IL IL207688A patent/IL207688A0/en unknown
-
2011
- 2011-01-07 US US12/986,707 patent/US9139651B2/en active Active
-
2015
- 2015-08-19 US US14/829,711 patent/US20150344581A1/en not_active Abandoned
-
2017
- 2017-01-20 US US15/411,640 patent/US20170137525A1/en not_active Abandoned
- 2017-06-06 US US15/615,567 patent/US20170275369A1/en not_active Abandoned
- 2017-12-12 US US15/839,362 patent/US20180094068A1/en not_active Abandoned
-
2018
- 2018-04-23 US US15/960,070 patent/US10611846B2/en not_active Expired - Lifetime
-
2020
- 2020-02-28 US US16/804,475 patent/US11312779B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525758A5 (cg-RX-API-DMAC10.html) | ||
| US11098117B2 (en) | Anti-CD137 antibodies and methods of use thereof | |
| US20220363757A1 (en) | Anti-lag-3 antibodies and compositions | |
| US11993653B2 (en) | Antibodies and methods of use thereof | |
| JP5985481B2 (ja) | 抗イディオタイプ抗体の迅速な産生 | |
| CN111867628A (zh) | 抗cd73抗体及其用途 | |
| CA3062061A1 (en) | Anti-tigit antibodies and methods of use thereof | |
| BRPI0516975A (pt) | anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno | |
| AU2019312565B2 (en) | Anti-MICA/B antibodies that block MICA/B shedding and methods of use | |
| JP2022514179A5 (cg-RX-API-DMAC10.html) | ||
| JP2002503676A5 (cg-RX-API-DMAC10.html) | ||
| RU2008132968A (ru) | Антитела к рецептору тимусного стромального лимфопоэтина | |
| JP2009518005A5 (cg-RX-API-DMAC10.html) | ||
| JP2016509585A5 (cg-RX-API-DMAC10.html) | ||
| JP2022545741A (ja) | 抗ｃｄ９６抗体およびその使用方法 | |
| WO2019179422A1 (en) | Novel bispecific pd-1/lag-3 antibody molecules | |
| IL277899B1 (en) | Methods and compositions for treating yellow fever | |
| HRP20120975T1 (hr) | Terapeutska upotreba anti-cs1 antitijela | |
| EP1972640A1 (en) | Apoptosis inducing antibodies | |
| CN111886024A (zh) | 抗tip-1抗体及其用途 | |
| US12030942B2 (en) | Anti-PD-1 antibodies and compositions | |
| CN119039448A (zh) | 特异性结合抗人tim-3抗体的抗独特型抗体及其用途 | |
| CA3059366C (en) | Anti-cd137 antibodies and methods of use thereof | |
| Zhao et al. | Endowing self-binding feature restores the activities of a loss-of-function chimerized anti-GM2 antibody | |
| JP2025504894A5 (cg-RX-API-DMAC10.html) |